Utløst oppgang av artikkel finans avisen "Vi kunne vært verdt 100 ganger mer"


Skal det komme noe godt ut av gamle Targovax? Virker som denne er glemt i det siste. Nå kan gjennombruddet komme med ny vaksine.

Nå halvert seg siden emisjonen på 2.50 kr. Kan det fortsatt være noe igjen i Circio?

Oppdatert 24.oktober:

"Circio selected to present its circVec circular RNA expression platform at the European Society of Cell and Gene Therapy (ESGCT) annual meeting in Rome 22-25 October; a prestigious and widely attended international gene therapy conference Circio presented new circVec protein expression data showing statistically
significant advantage vs. conventional mRNA-based vector expression both in vitro and in vivo The circVec 2.1 generation shows 15x increase in protein expression in vivo,
and has the potential to substantially improve on the performance of current gold-standard gene therapy approaches

Oslo, Norway 24 October 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces the publication of new, strong and statistically significant circVec circular RNA in vivo expression proof-of-concept data, presented both in the form of a poster and oral presentation by CTO, Dr. Thomas B Hansen, at the European Society of Cell and Gene Therapy (ESGCT) annual
meeting 2024.

"Circio continues to build momentum with the unique and powerful circVec platform. We selected the prestigious ESGCT meeting to present our latest results as it provided a great opportunity to showcase our technology to a broad life science industry and academic audience," said Dr. Thomas B. Hansen, CTO of
Circio. "circVec significantly outperforms mRNA-based expression both in vitro and in vivo and has the potential to offer substantial enhancement over current gold-standard gene therapy approaches."

In the ESGCT presentation, Circio showed the evolution and improvements of the circVec platform from the initial circVec 1.0 design to the current generation 2.1. Long-term in vivo experiments have now demonstrated that circVec 2.1 robustly outperforms classical mRNA-based expression over time, offering enhanced durability that reaches up to 15-fold higher reporter signals in mouse models. Additionally, a machine-learning approach to codon optimization has generated a novel circVec 2.2 design, delivering a further 2-4-fold increase in protein yield.

Circio is currently testing the performance of circVec 2.1 and 2.2 in both viral and DNA vector systems in multiple tissues and disease settings in vivo. These data will guide future development and partnering strategy for the circVec platform"


Oslo, Norway 19 November 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that it has entered a collaboration with Certest Biotec, S.L. for formulation of circVec into lipid nanoparticles (LNPs) for tissue specific delivery of DNA-vectors to address genetic disease.

"Circio´s powerful circVec-DNA technology achieves more than six months durability in mouse models on a single intra-muscular injection, with up to 15-fold increase in payload expression levels vs. standard mRNA-based vector systems" said Dr. Victor Levitsky, CSO of Circio. "Based on these promising findings in vivo, we are now looking for targeted delivery technology that can enable therapeutic application of circVec in specific tissues and diseases of
high unmet medical need. We selected Certest as a preferred partner for circVec-LNP formulation due to the impressive tissue specificity demonstrated for their proprietary nanoparticles."

"The library of ionizable lipids developed by our team is engineered for a wide range of nucleic acid payloads, exhibiting a great delivery capacity in preclinical studies and allows the production of thermostable LNPs." explained Dr. Juan Martínez Oliván, CSO of Certest Pharma, specialized unit in nucleic acids delivery systems at Certest Biotec. "Our capability to passively target different tissues unlocks the possibility to treat organ-specific diseases. We
are very enthusiastic about the joint formulation of Circio's new approach to circular RNA vector technology with our versatile ionizable lipids, creating a unique LNP-strategy for gene therapy treatment."

Under the collaboration, Certest has successfully performed packaging and in vitro validation of circVec-LNP formulations targeted for delivery to lung, liver and spleen, with positive technical results. Circio will now test these circVec-LNP formulations in vivo during the next 3-6 months to assess delivery efficiency, expression level and durability. If successful, these experiments can pave the way to development of multiple circVec therapeutic candidates in
the field of genetic diseases for both in-house development and partnering"

Oslo, Norway 5 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr.
Victor Levitsky are presenting updated data demonstrating the significant
advantages of Circio's circular RNA circVec platform compared to current mRNA
-based vector technology. The data further strengthens the in vitro and in vivo
validation of Circio's platform. The presentations are being delivered at two
major biopharma industry conferences in Basel, Switzerland, and Stockholm,
Sweden.

The presentations detail the advantages and potential of the circVec 3.0
generation to improve on current mRNA-based technology for a range of
therapeutic applications. In vivo expression data has shown an estimated circRNA
half-life of over 600 hours vs. under 10 hours for linear mRNA, which translates
to over 70 times prolonged RNA durability and 15 times enhanced protein
expression.

Novel systemic LNP-delivery data demonstrates robust and durable circVec
expression in spleen, far outperforming equivalent mRNA-vectors. This important
finding has the potential to open up attractive therapeutic opportunities for
the circVec technology in several areas, such as cell therapy. Further
experimental work is currently ongoing to validate and characterize these
observations.

"The recent results showing efficient and specific circVec delivery to spleen
are very promising and hints at novel opportunities for our circular RNA
platform in cell and immune therapies," said Dr. Victor Levitsky, CSO of
Circio. "A broad set of experiments to further investigate this observation, as
well as in vivo testing of the novel circVec 3.0 generation, will read out over
the next 6-12 weeks. The performance of circVec 3.0-AAV constructs is of
particular interest, which we believe has the potential to transform current
gold-standard AAV gene therapy and generate substantial partnering interest."